Fig. 1From: Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access programIncidence of varicella in immunocompromised participants. a Incidence in immunocompromised participants and subgroups and (b) incidence by timing of administration of VARIZIG. Percentage was calculated based on the number of participants with varicella outcome data (noted below the graph)Back to article page